Breakthrough Devices Program

A U.S. FDA program that grants expedited development and priority review to devices that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions for which no adequate alternatives exist. Designation gives the sponsor more interactive FDA engagement, sprint-style discussions, and prioritized review; several implanted BCIs have received it, given the severity and unmet need of their target indications.

Breakthrough designation speeds interaction and review — it does not lower the evidentiary standard for approval, guarantee approval, or ensure later reimbursement. It is easy to overread a designation announcement as a clinical endorsement, which it is not, and this misreading is a frequent source of hype in press coverage of neurotechnology.